According to foreign reports, the U.S. Food and Drug Administration (FDA) today opened a public consultation period on the application of PMI, which seeks to authorize the sale of iqos 3 heating non combustion (HNB) tobacco system as an improved risk tobacco product (MRTP).
Iqos 2.4 system was awarded the improved risk tobacco product sales on July 7, 2020, which is the first and only new tobacco nicotine product licensed through FDA's MRTP process.
The law requires the FDA's tobacco product center to conclude that the product is suitable for promoting public health.
Compared with iqos 2.4 devices, iqos 3 devices have many technological advances, including longer battery life and fast charging between two uses. It has passed the FDA's pre marketing review process and was approved for sale in the United States on December 7, 2020, and meets the standards that allow its sale to be suitable for the protection of public health.
The application highlights PMI's ongoing commitment to provide new innovations to U.S. adult smokers through the FDA process.
PMI is committed to a smoke-free future. We will completely replace cigarettes with scientifically proven smoke-free alternatives, which is a better choice for adults who would otherwise continue to smoke, said Jacek olczak, chief executive of PMI.
'our commitment to a science based future is unparalleled, with more than $8 billion invested in smoke-free products since 2008,' he said. The application highlights PMI's consistent commitment to provide new and innovative technologies to adult smokers in the United States through the FDA process. Our confidence in science; We believe that public supervision and open contact with the government are essential for a smoke-free future.